Vanguard Global Advisers
LBRX

Vanguard Global Advisers’s LB Pharmaceuticals LBRX Stock Holding History

Vanguard Global Advisers’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$284K Hold
8,753
– – ﹤0.01% 2354
2026
Q1 		$216K Buy
+8,753
New +$202K ﹤0.01% 2415

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return

Vanguard Global Advisers's LBRX Position: Q2 2026 in Review

Vanguard Global Advisers held its LB Pharmaceuticals (LBRX) position steady in Q2 2026 at 8,753 shares worth $284K. The position accounts for ﹤0.01% of the portfolio, ranked #2354.

Vanguard Global Advisers first reported a position in LBRX in Q1 2026 and has held it in 2 quarters since. 115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Vanguard Global Advisers held 8,753 shares of LB Pharmaceuticals worth $284K as of Q2 2026.
  • Vanguard Global Advisers left its LB Pharmaceuticals share count unchanged in Q2 2026.
  • LB Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2354 holding.
  • Vanguard Global Advisers first reported a position in LB Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.